Pharminent

AstraZeneca touts Brilinta CV benefit with new analysis

Days before the European Society of Cardiology’s 2017 Congress, the British pharma said an analysis of a prior study showed the drug lowered risk of cardiovascular death. http://www.biopharmadive.com/news/astrazeneca-touts-brilinta-cv-benefit-with-new-analysis/503426/

Filed under: Cardiovascular